Please upgrade your browser.
Stanford University School of Medicine scientist has generated a mutant version of the protein whose modified shape renders it substantially more potent than the natural protein while reducing its toxicity.
The International Alliance of Patients Organizations (IAPO) will launch its Patient-Centred Healthcare Indicators Review at its 5th Global Patients Congress in London, UK on 17-19 March 2012. Kidney Cancer Association (KCA) director Paula E. Bowen will represent the KCA's 70-thousand members from 102 nations.
The Medco drug interaction study looked at pharmacy claims of about 11,600 patients who had been prescribed any of nine oral drugs known as kinase inhibitors, used to treat a variety of cancers. They include Gleevec and Tasigna from Novartis; Pfizer Inc's Sutent; Nexavar from Onyx Pharmaceuticals Inc and Bayer AG; Tarceva, sold by Roche Holding and Japan's Astellas Pharma Inc; Sprycel from Bristol-Myers Squibb Co; and GlaxoSmithKline Plc's Tykerb.
Founded by Penn State football teammates, the Penn State Chapter of Uplifting Athletes has raised more than $600,000 for the Kidney Cancer Association since 2003.
Kidney cancer research at the University of North Carolina at Chapel Hill is getting a funding boost from SAIC-Frederick with the goal of developing new treatments for renal cell carcinoma, the most common type of kidney cancer in adults.
Rapid growth problems face the $53 billion Defense Health Program, which covers 9.7 million active and retired service members, their families, and eligible surviving family members of deceased active and retired service personnel.
Welcome to KidneyCancerCongress.org, where we are building the world's largest coalition of kidney cancer advocates. We are already collaborating with people in Russia, Poland, France, Italy, Singapore, United States, United Kingdom, and many other countries. Anyone with an interest in eradicating death and suffering from renal cancers is welcome to join.
A March 8, 2012 National Patient Advocate Foundation (NPAF) letter applauds Congressional efforts to better understand how the 340B program operates as it relates to the risk of improper purchases or diversion of 340B drugs, to facilitate Congressional oversight over the 340B program, and to ensure the 340B program is operating within the parameters of the law.
Increasing reactive oxygen species as a therapeutic approach to treat hereditary leiomyomatosis and renal cell carcinoma
Hereditary leiomyomatosis renal cell carcinoma (HLRCC)-associated renal tumors are aggressive and tend to metastasize early. There are currently no effective forms of therapy for patients with advanced HLRCC-associated kidney cancer.
Human VÎ³2Â VÎ´2-bearing T cells have recently received much attention in cancer immunotherapy. In this study, we conducted a phase I/II clinical trial of the adoptive transfer of Î³Î´ T cells to patients with advanced renal cell carcinoma.
|NeonCRM by Neon One|